What is Zacks Research’s Estimate for DNLI FY2024 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Zacks Research dropped their FY2024 earnings estimates for shares of Denali Therapeutics in a research note issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings of ($2.77) per share for the year, down from their prior forecast of ($2.71). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.51) EPS.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the firm posted ($0.72) EPS.

Several other analysts have also issued reports on the stock. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research report on Wednesday, January 15th. Robert W. Baird started coverage on Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price for the company. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. HC Wainwright dropped their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Denali Therapeutics Stock Up 0.7 %

NASDAQ:DNLI opened at $23.58 on Friday. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The business’s 50-day moving average price is $22.45 and its two-hundred day moving average price is $24.83.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC raised its position in Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC bought a new stake in Denali Therapeutics during the third quarter valued at about $73,000. Assetmark Inc. increased its position in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the period. Finally, KBC Group NV lifted its position in shares of Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after buying an additional 2,731 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the transaction, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,518 shares of company stock valued at $1,469,382. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.